Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/13136 |
Resumo: | Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2, evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). There is no treatment for Covid19, medications that soften the flu-like symptoms of the disease were used. In emergency cases, the combination of the antibiotic azithromycin and hydroxychloroquine, used for malaria and other medicines, was used. This study evaluated most of the drugs that are in use for the treatment of SARS-CoV-2, in order to present a drug or more that is effective for the treatment of the disease, also showing whether in vitro and in vivo research was conducted in the search for a better treatment. |
id |
UNIFEI_3076e2be565b8e5ce6387a872cb3ebe2 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/13136 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection Evaluación de los principales farmacoses utilizados para sars-cov-2: una prospección científica y tecnológica Avaliação dos principais fármacos utilizados para o sars-cov-2: uma prospecção cientifica e tecnológicaCovid-19CoronavírusSARS-CoV-2.CoronavirusCovid-19SARS-CoV-2.Coronavirus Covid-19SARS-CoV-2.Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2, evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). There is no treatment for Covid19, medications that soften the flu-like symptoms of the disease were used. In emergency cases, the combination of the antibiotic azithromycin and hydroxychloroquine, used for malaria and other medicines, was used. This study evaluated most of the drugs that are in use for the treatment of SARS-CoV-2, in order to present a drug or more that is effective for the treatment of the disease, also showing whether in vitro and in vivo research was conducted in the search for a better treatment.Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2 evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). Los coronavirus son virus que causan infecciones respiratorias que pueden afectar a animales y seres humanos. La epidemia del SARS-CoV-2, que causó covid-19, comenzó en Wuhan (China) en diciembre de 2019, y se extendió a varios países, convirtiéndose en una peligrosa pandemia sin tratamiento específico. Este trabajo tiene como objetivo mostrar los casos tratados con los principales fármacos para el SARS-CoV-2 evaluando su eficacia y desventajas. Entre la fecha (2019-2020) se utilizaron publicaciones con datos de tratamientos farmacológicos para el nuevo SARS-CoV-2, publicaciones científicas, organización mundial de la salud (OMS) y publicaciones gubernamentales.Os Coronavírus são vírus que causam infecções respiratórias podendo afetar animais e humanos. A epidemia de SARS-CoV-2, causador da COVID-19 teve início em Wuhan (China) em dezembro de 2019, e se espalhou por diversos países tornando-se uma pandemia perigosa e sem tratamento especifico. Esse trabalho pretende mostrar casos tratados com os principais fármacos para o SARS-CoV-2 avaliando sua eficácia e desvantagens. Foram utilizadas publicações com dados de tratamentos farmacológicos para o novo SARS-CoV-2, publicações cientificas, oficiais da Organização Mundial da Saúde (World Health Organization - WHO) e governamentais, dentre a data (2019-2020). Os dados foram coletados nas bases cientificas: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Biblioteca Virtual em saúde - BVS, SCIELO, Cochrane Library, HighWire Press, Scopus e Elsevier; e as bases tecnológicas: WIPO e INPI. A utilização desses fármacos pode ter ocasionado melhora e cura de pacientes globalmente. Acredita-se que são eficazes contra a doença. Porém, temos a necessidade de comprovações cientificas. Nos resultados observamos os fármacos utilizados mundialmente e as patentes aprovadas até (15/09/2020). Não existe tratamento para a Covid19, utilizou-se medicamentos amenizadores dos sintomas gripais da doença. Nos casos emergenciais foram utilizados a combinação do antibiótico azitromicina e hidroxicloroquina, usados para malária e outros medicamentos. Este trabalho avaliou grande parte dos medicamentos que estão em uso para o tratamento do SARS-CoV-2, com o intuito de apresentar um fármaco ou mais que seja eficaz para o tratamento da doença, mostrando ainda se foram realizadas pesquisas in vitro e in vivo na busca de uma melhor tratativa.Research, Society and Development2021-03-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1313610.33448/rsd-v10i3.13136Research, Society and Development; Vol. 10 No. 3; e19310313136Research, Society and Development; Vol. 10 Núm. 3; e19310313136Research, Society and Development; v. 10 n. 3; e193103131362525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/13136/11884Copyright (c) 2021 Kelly Maria Rêgo da Silva; Pryscilla Bizerra da Silva; Higo José Neri da Silva; Pauliana Texeira da Silva; Bruna Layra Silva; Ana Maria Castro Ferreira; Wallyson André dos Santos Bezerra; Denilson de Araújo e Silva; Mariel Rodrigues de Campos; Deylane Menezes Teles e Oliveira; Antonia Luzia Lima do Nascimento; Alice Maria de Castro Ribeiro; Amanda Miranda da Silva; Emille Andrade Sousa; Iara Katrynne Fonsêca Oliveira; Michelle Maria Ferreira Lopes; Nathália Batista de Andrade; Iluska Martins Pinheiro; Kivia Ludmilla Carvalho Ferreira; Denis Romulo Leite Furtadohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Kelly Maria Rêgo da Silva, Pryscilla Bizerra da Silva, Higo José Neri da Silva, Pauliana Texeira da Silva, Bruna Layra Ferreira, Ana Maria Castro Bezerra, Wallyson André dos Santos Silva, Denilson de Araújo e Campos, Mariel Rodrigues de Oliveira, Deylane Menezes Teles e Nascimento, Antonia Luzia Lima do Ribeiro, Alice Maria de Castro Silva, Amanda Miranda da Sousa, Emille Andrade Oliveira, Iara Katrynne Fonsêca Lopes, Michelle Maria Ferreira Andrade, Nathália Batista de Pinheiro, Iluska Martins Ferreira, Kivia Ludmilla Carvalho Furtado, Denis Romulo Leite 2021-03-28T12:03:35Zoai:ojs.pkp.sfu.ca:article/13136Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:34:33.110791Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection Evaluación de los principales farmacoses utilizados para sars-cov-2: una prospección científica y tecnológica Avaliação dos principais fármacos utilizados para o sars-cov-2: uma prospecção cientifica e tecnológica |
title |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection |
spellingShingle |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection Silva, Kelly Maria Rêgo da Covid-19 Coronavírus SARS-CoV-2. Coronavirus Covid-19 SARS-CoV-2. Coronavirus Covid-19 SARS-CoV-2. |
title_short |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection |
title_full |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection |
title_fullStr |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection |
title_full_unstemmed |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection |
title_sort |
Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection |
author |
Silva, Kelly Maria Rêgo da |
author_facet |
Silva, Kelly Maria Rêgo da Silva, Pryscilla Bizerra da Silva, Higo José Neri da Silva, Pauliana Texeira da Silva, Bruna Layra Ferreira, Ana Maria Castro Bezerra, Wallyson André dos Santos Silva, Denilson de Araújo e Campos, Mariel Rodrigues de Oliveira, Deylane Menezes Teles e Nascimento, Antonia Luzia Lima do Ribeiro, Alice Maria de Castro Silva, Amanda Miranda da Sousa, Emille Andrade Oliveira, Iara Katrynne Fonsêca Lopes, Michelle Maria Ferreira Andrade, Nathália Batista de Pinheiro, Iluska Martins Ferreira, Kivia Ludmilla Carvalho Furtado, Denis Romulo Leite |
author_role |
author |
author2 |
Silva, Pryscilla Bizerra da Silva, Higo José Neri da Silva, Pauliana Texeira da Silva, Bruna Layra Ferreira, Ana Maria Castro Bezerra, Wallyson André dos Santos Silva, Denilson de Araújo e Campos, Mariel Rodrigues de Oliveira, Deylane Menezes Teles e Nascimento, Antonia Luzia Lima do Ribeiro, Alice Maria de Castro Silva, Amanda Miranda da Sousa, Emille Andrade Oliveira, Iara Katrynne Fonsêca Lopes, Michelle Maria Ferreira Andrade, Nathália Batista de Pinheiro, Iluska Martins Ferreira, Kivia Ludmilla Carvalho Furtado, Denis Romulo Leite |
author2_role |
author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Kelly Maria Rêgo da Silva, Pryscilla Bizerra da Silva, Higo José Neri da Silva, Pauliana Texeira da Silva, Bruna Layra Ferreira, Ana Maria Castro Bezerra, Wallyson André dos Santos Silva, Denilson de Araújo e Campos, Mariel Rodrigues de Oliveira, Deylane Menezes Teles e Nascimento, Antonia Luzia Lima do Ribeiro, Alice Maria de Castro Silva, Amanda Miranda da Sousa, Emille Andrade Oliveira, Iara Katrynne Fonsêca Lopes, Michelle Maria Ferreira Andrade, Nathália Batista de Pinheiro, Iluska Martins Ferreira, Kivia Ludmilla Carvalho Furtado, Denis Romulo Leite |
dc.subject.por.fl_str_mv |
Covid-19 Coronavírus SARS-CoV-2. Coronavirus Covid-19 SARS-CoV-2. Coronavirus Covid-19 SARS-CoV-2. |
topic |
Covid-19 Coronavírus SARS-CoV-2. Coronavirus Covid-19 SARS-CoV-2. Coronavirus Covid-19 SARS-CoV-2. |
description |
Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2, evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). There is no treatment for Covid19, medications that soften the flu-like symptoms of the disease were used. In emergency cases, the combination of the antibiotic azithromycin and hydroxychloroquine, used for malaria and other medicines, was used. This study evaluated most of the drugs that are in use for the treatment of SARS-CoV-2, in order to present a drug or more that is effective for the treatment of the disease, also showing whether in vitro and in vivo research was conducted in the search for a better treatment. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-03-12 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/13136 10.33448/rsd-v10i3.13136 |
url |
https://rsdjournal.org/index.php/rsd/article/view/13136 |
identifier_str_mv |
10.33448/rsd-v10i3.13136 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/13136/11884 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 3; e19310313136 Research, Society and Development; Vol. 10 Núm. 3; e19310313136 Research, Society and Development; v. 10 n. 3; e19310313136 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052746340237312 |